Key result
Extracellular microRNAs were differentially expressed in cardiomyocytes derived from induced pluripotent stem cells of arrhythmogenic cardiomyopathy patients compared to healthy donors.
Why the study?
Differential diagnosis of ACM during the latent phase is clinically challenging, necessitating the identification of early biomarkers.
May identify extracellular nucleic acids as latent ACM biomarkers; hypothesis-generating in iPSC models and requires clinical validation.
Differential diagnosis of arrhythmogenic cardiomyopathy (ACM) during the disease latent phase is a challenging clinical problem that requires identification of early ACM biomarkers. Because extracellular nucleic acids are stable, specific, and can be easily detected, they can be used as reliable biomarkers of various diseases. In this study, we analyzed the levels of extracellular microRNAs and mitochondrial DNA in the conditioned medium collected from cardiomyocytes differentiated from induced pluripotent stem cells of ACM patients and healthy donor. Several microRNAs were expressed differently by the affected and healthy cardiomyocytes; therefore, they could be considered as potential ACM biomarkers.
No takes yet. Share an insight, caveat, or question.
Khudiakov et al. (2019) studied Arrhythmogenic cardiomyopathy. Extracellular microRNAs and mitochondrial DNA vs. Healthy donor cardiomyocytes was evaluated on Expression levels of extracellular microRNAs and mitochondrial DNA. Extracellular microRNAs were differentially expressed in cardiomyocytes derived from induced pluripotent stem cells of arrhythmogenic cardiomyopathy patients compared to healthy donors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: